



REINSURANCE HOT NEWS

January 26th, 2021

Addition of 3 New High Cost Specialty Drugs to BIO Case Covered Services

The following drugs have been added to the High Cost Specialty Drug BIO case type reinsured services effective 10/01/2020.

- Vyondys (Duchenne muscular dystrophy [DMD])
- Viltepsso (Duchenne muscular dystrophy [DMD])

The following drug has been added to the High Cost Specialty Drug BIO case type reinsured services effective 11/23/2020.

- Oxlumo (primary hyperoxaluria type 1 [PH1])

The process for Reinsurance for the drug will be the same as for other Biological/High Cost Specialty Drugs – see the Reinsurance Manual for details.
